Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)

NCT06229041 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

472

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: Camrelizumab ＋Immunotherapy

Sponsor

Peking University Cancer Hospital & Institute

Collaborators

[object Object]